Desmopressin (DDAVP): The Vasopressin Analog With Targeted Antidiuretic Activity

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is Desmopressin?

Desmopressin (1-deamino-8-D-arginine vasopressin, abbreviated DDAVP) is a synthetic analog of the naturally occurring posterior pituitary hormone arginine vasopressin (AVP, also known as antidiuretic hormone or ADH). Developed in 1977, desmopressin incorporates two structural modifications compared to native vasopressin: deamination of the N-terminal cysteine and substitution of L-arginine at position 8 with D-arginine. These changes produce a molecule with dramatically enhanced selectivity for the vasopressin V2 receptor, prolonged duration of action, and minimal vasopressor activity.

Desmopressin is among the most widely prescribed peptide pharmaceuticals globally, with established indications spanning endocrinology, urology, and hematology. Its targeted pharmacology — retaining the antidiuretic action of vasopressin while eliminating its cardiovascular effects — exemplifies rational drug design in peptide therapeutics. For context on other hormonal peptides, see our guide to hormonal and reproductive peptides.

Property	Detail
Generic Name	Desmopressin acetate
Brand Names	DDAVP, Stimate, Nocdurna, Noctiva
Structure	Modified nonapeptide (deamino-Cys1, D-Arg8)
Molecular Weight	~1,069 Da
Receptor Selectivity	V2 >> V1a (3,000:1 selectivity ratio)
Half-Life	2–4 hours (IV), 3.3–3.5 hours (intranasal)
Antidiuretic:Vasopressor Ratio	~3,000:1 (vs. 1:1 for native vasopressin)
Formulations	Intranasal spray, oral tablets, sublingual melt, IV/SC injection
FDA Status	Approved for multiple indications

Mechanism of Action

Desmopressin acts primarily through the vasopressin V2 receptor (V2R), a Gs-coupled GPCR expressed predominantly in the basolateral membrane of principal cells in the renal collecting duct. Activation of V2R stimulates adenylyl cyclase, increasing intracellular cAMP, which activates protein kinase A (PKA). PKA phosphorylates aquaporin-2 (AQP2) water channels stored in intracellular vesicles, triggering their translocation and insertion into the apical (luminal) membrane of collecting duct cells.

Renal Effects

• Water reabsorption: Inserted AQP2 channels allow osmotic water reabsorption from the collecting duct lumen back into the medullary interstitium, concentrating urine and reducing urine volume.
• Urine concentration: Desmopressin can increase urine osmolality from as low as 50 mOsm/kg to over 1,000 mOsm/kg in responsive patients.
• Duration: Effects last 8–12 hours with intranasal administration, compared to 2–3 hours for native vasopressin.

Hemostatic Effects

• Factor VIII release: Desmopressin stimulates the release of von Willebrand factor (vWF) and factor VIII from endothelial cell Weibel-Palade bodies via V2 receptor activation on vascular endothelium.
• vWF increase: A single dose can increase vWF levels 2- to 5-fold, improving primary hemostasis in patients with mild hemophilia A and certain subtypes of von Willebrand disease.
• Tachyphylaxis: Repeated doses within 48 hours show diminishing responses as Weibel-Palade body stores are depleted.

Research and Clinical Applications

Central Diabetes Insipidus

The primary endocrine indication for desmopressin is central diabetes insipidus (CDI), a condition caused by insufficient vasopressin production or secretion from the posterior pituitary. Patients with CDI produce copious dilute urine (up to 20 liters/day) and experience severe thirst. Desmopressin replacement therapy effectively controls polyuria and polydipsia, typically with twice-daily intranasal or oral dosing titrated to urine output.

Primary Nocturnal Enuresis

Desmopressin is FDA-approved for the treatment of primary nocturnal enuresis (bedwetting) in children aged 6 years and older. By reducing overnight urine production, desmopressin decreases the frequency of enuretic episodes. Response rates range from 60–70% for reduced wet nights, though relapse after discontinuation is common, and the medication is typically used as a management tool rather than a cure.

Hemophilia A and von Willebrand Disease

Desmopressin (as Stimate nasal spray or IV DDAVP) is a first-line treatment for mild hemophilia A (factor VIII levels 5–40%) and type 1 von Willebrand disease. By releasing stored factor VIII and vWF, desmopressin can provide sufficient hemostasis for minor surgical procedures, dental extractions, and menorrhagia without the need for factor concentrate replacement.

Nocturia in Adults

Low-dose desmopressin formulations (Nocdurna sublingual melt, Noctiva nasal spray) have been approved for the treatment of nocturia due to nocturnal polyuria in adults. These formulations use gender-specific dosing (lower doses in women, who are more susceptible to hyponatremia) and require serum sodium monitoring.

Safety and Tolerability

The most clinically significant adverse effect of desmopressin is hyponatremia (low serum sodium), which occurs when excessive water retention dilutes serum sodium below 135 mEq/L. Severe hyponatremia (below 120 mEq/L) can cause seizures, cerebral edema, and death. Risk factors include excessive fluid intake during desmopressin use, advanced age, low baseline sodium, and concomitant medications that impair free water excretion.

Other adverse effects include headache, nausea, nasal congestion (intranasal formulations), and facial flushing. Because of hyponatremia risk, baseline and periodic serum sodium monitoring is recommended, and patients must be counseled to restrict fluid intake during the period of desmopressin activity. The medication is contraindicated in patients with habitual or psychogenic polydipsia and in those with moderate to severe renal impairment.

Regulatory Status

Desmopressin is one of the most well-established peptide pharmaceuticals, with FDA approvals spanning multiple indications and formulations. Brand names include DDAVP (intranasal and oral), Stimate (high-concentration nasal spray for hemostatic indications), Nocdurna (sublingual melt for nocturia), and Noctiva (nasal spray for nocturia). Generic formulations are widely available. It is a prescription medication requiring medical supervision, particularly for sodium monitoring.